New psoriasis pill aims to stop the itch and boost confidence

NCT ID NCT05701995

Completed Symptom relief Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

Summary

This study tested whether a medication called deucravacitinib could improve the daily life and well-being of people living with plaque psoriasis. It involved 180 adults with moderate-to-severe psoriasis who were already candidates for systemic treatment. Participants were randomly assigned to receive either the active drug or a placebo for 16 weeks to see which group reported better quality of life, less itching, and clearer skin.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Local Institution - 0001

Rochester, New York, 14623, United States
Local Institution - 0002

Waterford, Michigan, 48328, United States
Local Institution - 0003

Baton Rouge, Louisiana, 70809, United States
Local Institution - 0004

Bakersfield, California, 93309, United States
Local Institution - 0005

Bexley, Ohio, 43209, United States
Local Institution - 0006

Phoenix, Arizona, 85006, United States
Local Institution - 0007

Rolling Meadows, Illinois, 60008, United States
Local Institution - 0008

South Jordan, Utah, 84095, United States
Local Institution - 0009

Sacramento, California, 95815, United States
Local Institution - 0010

Auburn Hills, Michigan, 48326, United States
Local Institution - 0012

Mayfield Heights, Ohio, 44124, United States
Local Institution - 0013

New York, New York, 10128, United States
Local Institution - 0014

Spokane, Washington, 99202, United States
Local Institution - 0015

North Little Rock, Arkansas, 72117, United States
Local Institution - 0016

Coral Gables, Florida, 33134, United States
Local Institution - 0017

Las Vegas, Nevada, 89148, United States
Local Institution - 0018

Rockville, Maryland, 20850, United States
Local Institution - 0019

Charleston, South Carolina, 29407, United States
Local Institution - 0020

Snellville, Georgia, 30078, United States
Local Institution - 0021

Bellevue, Washington, 98004, United States
Local Institution - 0022

San Diego, California, 92103, United States
Local Institution - 0024

Washington D.C., District of Columbia, 20016, United States
Local Institution - 0025

Skokie, Illinois, 60077, United States
Local Institution - 0027

Brandon, Florida, 33511, United States
Local Institution - 0028

Frisco, Texas, 75034, United States
Local Institution - 0029

Cypress, Texas, 77433, United States
Local Institution - 0030

Centennial, Colorado, 80111, United States
Local Institution - 0031

Mill Creek, Washington, 98012, United States
Local Institution - 0032

New York, New York, 10011, United States
Local Institution - 0033

Springville, Utah, 84663, United States
Local Institution - 0034

Scottsdale, Arizona, 85260, United States
Local Institution - 0035

Reno, Nevada, 89509, United States
Local Institution - 0036

Springfield, Illinois, 62703, United States
Local Institution - 0037

Atlanta, Georgia, 30331, United States
Local Institution - 0038

Carolina, 00985, Puerto Rico
Local Institution - 0039

San Juan, 00917, Puerto Rico
Local Institution - 0040

Caguas, 00727, Puerto Rico
Riverchase Dermatology

Pembroke Pines, Florida, 33028, United States

Conditions

Explore the condition pages connected to this study.

PSORIASIS